Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Barrier agents

Malatesta35 proposed the key intermediate product (compound 28) of the oxidative degradation of photochromic spirooxazines. These species may result from the photochromic irreversible degradation of the spirooxazines even under conditions of partial or total absence of oxidation as, for example, in polymers coated with thin films of barrier agents such as SiO 2, SiOxCy, AI2O3, and MgO. [Pg.100]

Dimer quaternary compounds, (11), prepared by the author [4] were used as barrier agents in personal care products. [Pg.399]

Mucosal barrier agents form a protective barrier against acid and pepsin. [Pg.115]

Sucralfate (Carafate) is a mucosal barrier agent and must be administered on an empty stomach for the medication to coat the stomach lining. The nurse should question the time the medication is scheduled for and arrange for the medication to be administered at 0730. [Pg.119]

Sucralfate (Carafate) is a mucosal barrier agent that coats the stomach lining. Protonix does not coat the stomach. [Pg.157]

A mucosal barrier agent to a male client who has peptic ulcer disease. [Pg.265]

At 0900 the breakfast tray should have already been consumed. Administering a mucosal barrier agent after a meal places medication in the stomach that will coat the food, not the stomach lining. This medication should be retimed for 0730 and not administered until later in the morning after the breakfast meal has had a chance to leave the stomach. [Pg.276]

This is the mechanism of action for mucosal barrier agents. [Pg.414]

Slip additives Other stabilisers Gas barrier agents... [Pg.32]

Film or sheet generally function as supports for other materials, as barriers or covers such as packaging, as insulation, or as materials of constmction. The uses depend on the unique combination of properties of the specific resins or plastic materials chosen. When multilayer films or sheets are made, the product properties can be varied to meet almost any need. Further modification of properties can be achieved by use of such additives or modifiers as plasticizers (qv), antistatic agents (qv), fire retardants, sHp agents, uv and thermal stabilizers, dyes (qv) or pigments (qv), and biodegradable activators. [Pg.373]

Alkenylsuccinic anhydrides made from several linear alpha olefins are used in paper sizing, detergents, and other uses. Sulfosuccinic acid esters serve as surface active agents. Alkyd resins (qv) are used as surface coatings. Chlorendric anhydride [115-27-5] is used as a flame resistant component (see Flame retardants). Tetrahydrophthalic acid [88-98-2] and hexahydrophthalic anhydride [85-42-7] have specialty resin appHcations. Gas barrier films made by grafting maleic anhydride to polypropylene [25085-53-4] film are used in food packaging (qv). Poly(maleic anhydride) [24937-72-2] is used as a scale preventer and corrosion inhibitor (see Corrosion and corrosion control). Maleic anhydride forms copolymers with ethylene glycol methyl vinyl ethers which are partially esterified for biomedical and pharmaceutical uses (189) (see Pharmaceuticals). [Pg.461]

The phenoHc resins used for particle board are NaOH-catalyzed resoles of low viscosity and high water miscibility, similar to the Hquid resole adhesives used in plywood manufacture. The higher resin and caustic content of the board frequently necessitates the addition of hydrophobic agents such as wax emulsions to increase the barrier properties of the board. The adhesive is appHed to the particles in thin streams using high agitation to maximize material usage. Boards are cured in presses for 5—10 min at 150—185°C. [Pg.306]

Certain neutral technetium complexes can be used to image cerebral perfusion (Fig. 4). Those in Figure 4a and 4b have been approved for clinical use. Two other complexes (Fig. 4c and 4d) were tested in early clinical trials, but were not developed further. An effective cerebral perfusion agent must first cross the blood brain barrier and then be retained for the period necessary for image acquisition. Tc-bicisate is retained owing to a stereospecific hydrolysis in brain tissue of one of the ester groups to form the anionic complex TcO(ECD) , which does not cross the barrier. This mechanism of retention is termed metaboHc trapping. [Pg.478]

An inversion of these arguments indicates that release agents should exhibit several of the following features (/) act as a barrier to mechanical interlocking (2) prevent interdiffusion (J) exhibit poor adsorption and lack of reaction with at least one material at the interface (4) have low surface tension, resulting in poor wettabihty, ie, negative spreading coefficient, of the release substrate by the adhesive (5) low thermodynamic work of adhesion ... [Pg.100]

An excellent review of composite RO and nanofiltration (NE) membranes is available (8). These thin-fHm, composite membranes consist of a thin polymer barrier layer formed on one or more porous support layers, which is almost always a different polymer from the surface layer. The surface layer determines the flux and separation characteristics of the membrane. The porous backing serves only as a support for the barrier layer and so has almost no effect on membrane transport properties. The barrier layer is extremely thin, thus allowing high water fluxes. The most important thin-fHm composite membranes are made by interfacial polymerization, a process in which a highly porous membrane, usually polysulfone, is coated with an aqueous solution of a polymer or monomer and then reacts with a cross-linking agent in a water-kniniscible solvent. [Pg.144]


See other pages where Barrier agents is mentioned: [Pg.205]    [Pg.1790]    [Pg.105]    [Pg.57]    [Pg.59]    [Pg.276]    [Pg.63]    [Pg.205]    [Pg.1790]    [Pg.105]    [Pg.57]    [Pg.59]    [Pg.276]    [Pg.63]    [Pg.338]    [Pg.2912]    [Pg.89]    [Pg.197]    [Pg.476]    [Pg.382]    [Pg.430]    [Pg.448]    [Pg.205]    [Pg.243]    [Pg.93]    [Pg.321]    [Pg.518]    [Pg.10]    [Pg.373]    [Pg.383]    [Pg.306]    [Pg.459]    [Pg.385]    [Pg.443]    [Pg.511]    [Pg.155]    [Pg.283]    [Pg.432]    [Pg.85]    [Pg.464]   
See also in sourсe #XX -- [ Pg.59 ]




SEARCH



Barrier approach blood agents

Barrier approach chemical agent

Blood-brain barrier crossing agents

Blood-brain barrier crossing agents agonists

Mucosal barrier agents

© 2024 chempedia.info